SOURCE: Streetwise Reports

Streetwise Reports

December 28, 2015 09:00 ET

The Life Sciences Report Announces the RestorGenex and Diffusion Pharmaceuticals Merger

SAN FRANCISCO, CA--(Marketwired - December 28, 2015) - The merger of RestorGenex Corp. (OTCQX: RESX) and privately held Diffusion Pharmaceuticals LLC, announced Tuesday, Dec. 15, will create an oncology-focused clinical-stage company with a diversified development portfolio of product candidates addressing novel targets, including several orphan indications, according to a press release issued by the companies. The combined company will be named Diffusion Pharmaceuticals Inc. and will be headquartered in Charlottesville, Virginia.

RestorGenex, a specialty biopharmaceutical company with a $24.2 million ($24M) market cap, is focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. RestorGenex's lead product is a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase 1 clinical trials for age-related macular degeneration, and is in preclinical development for GBM. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. The company believes its compounds and inhibitors may have utility in a number of additional diseases.

Diffusion Pharmaceuticals is a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients by…

Continue reading this interview: RestorGenex and Diffusion Pharmaceuticals Announce Merger to Form Oncology Biotech Company.

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

RestorGenex is a sponsor of Streetwise Reports. RestorGenex had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of RestorGenex and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Contact Information